Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dicot Pharma ABFRA:KN0 +1.35%18 Cash Ratio is 28.88 as of Jun. 2026, which is 370% above its 10-year median of 6.15. GuruFocus rates FRA:KN0 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 965 Drug Manufacturers companies, Dicot Pharma AB ranks better than 99.07% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Dicot Pharma AB Cash Ratio Related Terms
Dicot Pharma AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Dicot Pharma AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dicot Pharma AB (FRA:KN0) has a Cash Ratio of 28.88 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Dicot Pharma AB and its competitors. This is 370% above median its historical median of 6.15. Over the past decade, Dicot Pharma AB's Cash Ratio has ranged from 0.26 to 28.88. According to the industry distribution chart, Dicot Pharma AB ranks #9 out of 965 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Dicot Pharma AB's Cash Ratio too high?
Dicot Pharma AB's current Cash Ratio of 28.88 is 370% above median its 10-year median of 6.15. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 28.88. The Drug Manufacturers industry median Cash Ratio is 0.57. Dicot Pharma AB's value of 28.88 is 4966.7% above this industry median. Based on the distribution chart, Dicot Pharma AB ranks #9 out of 965 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #9 out of 965 companies for Cash Ratio. This places Dicot Pharma AB in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.57. Dicot Pharma AB's value of 28.88 is 4966.7% above this benchmark. Historically, Dicot Pharma AB's own Cash Ratio has ranged from 0.26 to 28.88 over the past decade. While the company's 10-year median is 6.15 vs. the industry median of 0.57, Dicot Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dicot Pharma AB's current Cash Ratio of 28.88 is 4966.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current Cash Ratio is 28.88, which is 370% above median its own 10-year median of 6.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (FRA:KN0) has a current Cash Ratio of 28.88. The current Cash Ratio is 28.88, which is 370% above median its 10-year median of 6.15 and 4966.7% above the Drug Manufacturers industry median of 0.57. Dicot Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Dicot Pharma AB (FRA:KN0), the current Cash Ratio is 28.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
18GF Score
Get the complete analysis for FRA:KN0
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN0 has been successfully added to your 
